Bellicum Pharmaceuticals

$4.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-2.24%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell BLCM and other stocks, options, and ETFs commission-free!

About BLCM

Bellicum Pharmaceuticals, Inc. Common Stock, also called Bellicum Pharmaceuticals, is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. The listed name for BLCM is Bellicum Pharmaceuticals, Inc. Common Stock.

CEO
Richard A. Fair
Employees
107
Headquarters
Houston, Texas
Founded
2004
Market Cap
22.85M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
711.75K
High Today
$4.69
Low Today
$4.22
Open Price
$4.56
Volume
477.91K
52 Week High
$9.56
52 Week Low
$2.62

BLCM Earnings

-$7.81
-$4.84
-$1.88
$1.09
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, After Hours

You May Also Like

EBAY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure